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Introduction: HER2-enriched subtype has been associated with higher response to
neoadjuvant anti-HER2-based therapy across various clinical trials. However, limited
data exist in real-world practice and regarding residual disease. Here, we evaluate the
association of HER2-enriched with pathological response (pCR) and gene expression
changes in pre- and post-treatment paired samples in HER2-positive breast cancer
patients treated outside of a clinical trial.
Methods: We evaluated clinical-pathological data from a consecutive series of 150
patients with stage II-IIIC HER2-positive breast cancer treated from August 2004
to December 2012 with trastuzumab-based neoadjuvant chemotherapy. Expression
of 105 breast cancer-related genes, including the PAM50 genes, was determined
in available pre-and post-treatment formalin-fixed paraffin-embedded tumor samples
using the nCounter platform. Intrinsic molecular subtypes were determined using the
research-based PAM50 predictor. Association of genomic variables with total pCR
was performed.
Results: The pCR rate was 53.3%, with higher pCR among hormonal receptor
(HR)-negative tumors (70 vs. 39%; P < 0.001). A total of 89 baseline and 28
residual tumors were profiled, including pre- and post-treatment paired samples
from 26 patients not achieving a pCR. HER2-enriched was the predominant
baseline subtype not only in the overall and HR-negative cohorts (64 and
75%, respectively), but also in the HR-positive cohort (55%). HER2-enriched
was associated with higher pCR rates compared to non-HER2-enriched
subtypes (65 vs. 31%; OR = 4.07, 95% CI 1.65–10.61, P < 0.002) and this
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association was independent of HR status. In pre- and post-treatment paired samples
from patients not achieving a pCR, a lower proportion of HER2-enriched and twice
the number of luminal tumors were observed at baseline, and luminal A was the most
frequent subtype in residual tumors. Interestingly, most (81.8%) HER2-enriched tumors
changed to non-HER2-enriched, whereas most luminal A samples maintained the same
subtype in residual tumors.
Conclusions: Outside of a clinical trial, PAM50 HER2-enriched subtype predicts
pCR beyond HR status following trastuzumab-based chemotherapy in HER2-positive
disease. The clinical value of intrinsic molecular subtype in residual disease warrants
further investigation.
Keywords: breast cancer, HER2, pathological complete response, gene expression, molecular intrinsic subtype,
residual disease, paired samples
INTRODUCTION
Significant advances have occurred in the treatment of HER2-
positive breast cancer that have dramatically improved survival
and changed its natural history (1–6). In the neoadjuvant setting,
the introduction of HER2-targeted agents to chemotherapy
has considerably enhanced the achievement of a pathological
complete response (pCR) (7–10). This has translated into
important gains in survival in early HER2-positive disease (11–
13). Despite these improvements, HER2-positive breast cancer
remains a clinically and biologically heterogeneous disease with
different treatment sensitivities and survival outcomes (14–16).
Thus, identification of these distinct groups of patients using
molecular-based biomarkers is needed.
Among different molecular biomarkers evaluated to date
in HER2-positive disease, intrinsic molecular subtypes (i.e.,
luminal A, luminal B, HER2-enriched, and basal-like) identified
by gene expression analysis have now shown consistent data
across several clinical trials. Specifically, the HER2-enriched
subtype has been associated with a higher likelihood of achieving
a pCR following neoadjuvant anti-HER2-based chemotherapy
compared to non-HER2-enriched disease (15, 17–21). However,
limited data exist to date (1) outside a clinical trial setting and
(2) regarding residual disease and gene expression changes in
paired samples.
Based on this prior evidence, the primary aim of this study was
to test the association of the HER2-enriched subtype with pCR
in a consecutive series of HER2-positive breast cancer patients
homogeneously treated with trastuzumab-based neoadjuvant
chemotherapy at a single comprehensive cancer center. As a
secondary aim, we explored biological changes between baseline
and surgery specimens in patients with residual disease after




Clinicopathological data were evaluated in a series of 150
women with stages II to IIIC (T4d included) HER2-positive
breast cancer consecutively treated at Institut Català d’Oncologia
(ICO)-Hospitalet (Barcelona, Spain) between August 2004 and
December 2012. Treatment schema consisted of weekly paclitaxel
80 mg/m2 for 12 weeks followed by 4 cycles of 5-Fluoracil,
Epirubicin, and Cyclophosphamide (600/75/60 mg/m2) every 21
days. During the 24 weeks of neoadjuvant systemic treatment,
concomitant trastuzumab 2 mg/kg (after a 4 mg/kg loading
dose) was administered. Surgery was performed 3–4 weeks after
the last dose of chemotherapy. Left ventricular ejection fraction
was monitored every 12 weeks during treatment and in the
follow-up period every 6 months for the first 2 years and then
annually. Adjuvant hormonal therapy and radiotherapy were
administered per institutional guidelines. Additional 6 months
of adjuvant trastuzumab were also recommended since 2006.
This study was approved by the Institutional Review Board of
H.U. Bellvitge, L’Hospitalet (Barcelona), and all patients signed
informed consent forms to allow molecular analyses to be
performed on their tissue samples.
Estrogen receptor (ER) and progesterone receptor (PR) status
were determined by immunohistochemistry (IHC) at baseline
core biopsies and in post-treatment surgical specimens with
residual disease and considered positive if >1% of tumor cells
were stained. HER2 positivity was determined by IHC and
fluorescence in situ hybridization according to 2007 ASCO/CAP
guidelines (23). pCRwas defined as the absence of invasive cancer
both in the breast and lymph nodes, regardless of the presence of
in situ carcinoma (ypT0/isypN0).
Gene Expression Analysis and Intrinsic
Subtyping
Hematoxylin and eosin-stained slides from formalin-fixed
paraffin-embedded (FFPE) baseline core biopsies and post-
neoadjuvant surgical specimens of patients with residual disease
were examined to confirm the presence of invasive tumor
cells and to determine the minimum surface area. For RNA
purification, 1–5 10 µm FFPE slides were used for each
tumor specimen. A minimum of 100 ng of total RNA
was used to measure the expression of 105 breast cancer-
related genes, including the PAM50 genes, 5 housekeeping
genes, and 50 additional genes (related to proliferation, cell
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data n = 91
Age, median (range) 50 (27–79) 51 (27–76)
HISTOLOGICAL GRADE
Grade 2 47 (31.3%) 33 (36.3%)
Grade 3 101 (67.3%) 57 (62.6%)
Not evaluable 2 (1.3%) 1 (1.1%)
TUMOR STAGE
T1 9 (6.0%) 7 (7.8%)
T2 97 (64.7%) 55 (61.1%)
T3 15 (10.0%) 8 (8.9%)
T4b 16 (10.6 %) 10 (11.1%)
T4d 13 (8.7%) 10 (11.1%)
NODAL STATUS
N0 34 (22.5%) 18 (20%)
N1 90 (59.6%) 57 (63.3%)
N2 15 (9.9%) 10 (11.1%)
N3 11 (7.3%) 5 (5.6%)
HORMONAL RECEPTOR STATUS
ER+ PR+ 56 (37.4%) 36 (39.6%)
ER+ PR– 22 (14.4%) 11(12.1%)
ER– PR+ 2 (1.2%) 2 (2.2%)
ER– PR– 70 (47.0%) 42 (46.1%)
Ki67
<20 27 (18.0%) 18 (19.8%)
≥20 119 (79.3%) 73 (80.2%)
Not evaluable 4 (2.7%)
ER, estrogen receptor; PR, progesterone receptor.
cycle, and angiogenesis/hypoxia). Gene expression analyses and
comparison of pre- and post-treatment samples were performed
at Vall d’Hebron Institute of Oncology (VHIO) using the
nCounter platform (Nanostring Technologies, Seattle, WA,
USA). Data were log base 2 transformed and normalized using
housekeeping genes selected.
Intrinsic subtyping (luminal A, luminal B, HER2-enriched,
basal-like, and normal-like) was performed using the research-
based PAM50 intrinsic subtype predictor as previously
described (24, 25).
Statistical Analysis
Association between two variables was evaluated using Student’s
t-test, Pearson’s χ2 test or Fisher’s exact test. Univariate and
multivariate logistic regression analyses were done to investigate
the association of each variable with pCR. Odds ratios (OR) and
95% confidence intervals (CI) were calculated for each variable.
The significance level was set to a two-sided α of 0.05. To identify
genes whose expression was significantly different between paired
pre- and post-treated samples, we used a paired two-class
significance analysis of microarrays (SAM) with a false discovery
rate (FDR) <5%. All statistical tests were two sided, and the
statistical significance level was set to <0.05. We used R version
3.2.2 for all the statistical analyses (http://cran.r-project.org).
RESULTS
Baseline clinicopathologic characteristics of the overall cohort of
patients (n = 150) and from those with tissue samples available
for gene expression (n = 91) are listed in Table 1. A flow
diagram of the study population is shown in Figure S1. The
baseline median tumor size was 30mm and 35% of patients
had locally advanced breast cancer. All 150 patients underwent
surgery; therefore, all were evaluable for pathological response.
Lumpectomy was performed in 87 patients (58%). Overall, 80
of 150 patients (53.3%, 95% CI 0.45–0.61) achieved a pCR in
the breast and lymph nodes. Interestingly, 10 patients out of
13 (77%) with inflammatory breast cancer experienced a pCR.
HR-negative disease was significantly associated with higher pCR
rates (69.6% [48/69] vs. 39.5% [32/81] in HR-positive; p< 0.001).
Age, tumor size, histological differentiation grade, or Ki67 were
not associated with pCR.
With a median of follow-up of 79 months (range 15–141
months), median disease-free survival (DFS) was not reached
(Figure 1A); DFS was 83% (95% CI 72.1–87.6%). There were
25 relapses (16.7%): 16 patients had initially HR-positive tumors
and 9 HR-negative tumors. Median time to progression was 32
months (range 8–96 months). This time differed significantly
per HR status: 19.8 months in HR-negative tumors and double
(39.5 months) in HR-positive ones (p = 0.023). Achieving a pCR
was significantly associated with an improved DFS in the overall
cohort (Figure 1B) and by HR status (Figure S2). There were 7
relapses (8.7%) in the pCR group vs. 18 (25.7%) in the group of
residual disease (p = 0.005, OR 3.28, 95% CI 1.37–7.86). Median
overall survival (OS) was not reached (Figure 1C). OS was 88.7%
(95% CI 70.6–91.8%). There were 17 deaths, the majority due
to disease progression and 3 due to other causes (none of these
related to treatment). In contrast to DFS, achieving a pCR was
not significantly associated with an improved OS (Figure 1D).
Baseline Subtype Distribution
Of the 89 available baseline samples for gene expression analyses,
40 were HR-negative and 49 were HR-positive. At baseline, most
tumors were classified as HER2-enriched subtype by PAM50
(64%), followed by luminal A (11.2%), normal-like (9%) basal-
like (7.9%), and luminal B (7.9%). Subtype distribution differed
significantly between HR-status. Basal-like subtype was identified
only in HR-negative disease, whereas luminal A and B were
identified only inHR-positive samples (Figure 2) HER2-enriched
was the predominant one in both HR-negative tumors (75%) and
HR-positive tumors (55%).
Association of Intrinsic Subtypes and Gene
Expression With pCR
Higher rates of pCR were observed in HER2-enriched tumors
compared to non-HER2-enriched subtypes (64.9 vs. 31.2%, OR
= 4.07, 95% CI 1.65–10.61, p < 0.002) regardless of HR status
(Figure 3). None of the luminal A samples achieved a pCR and
only two samples with luminal B disease (28.6%) achieved a pCR.
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FIGURE 1 | Disease Free Survival of the entire cohort (A) and based on pathological complete response (pCR) (B). Overall Survival (OS) of the entire cohort (C) and
based on pCR (D).
We evaluated the association between PAM50 signatures, HR
status (by IHC), and ki67 (by IHC and by gene expression) with
pCR. HR-negative status and five of the eight PAM50 signatures
(HER2-enriched, ROR-S based on subtype contents, ROR-P
based on subtype contents and proliferation index, Basal-like,
and Proliferation score) were significantly associated with pCR,
whereas luminal A was associated with non-pCR (p < 0.001).
HR-negative status, HER2-enriched and luminal A signatures
demonstrated the strongest association in predicting pathological
response (Figure 4A). After adjusting for HR status, HER2-
enriched, ROR-S and ROR-P were significantly associated with
pCR and luminal A with non-pCR (Figure 4B).
We then assessed the association between individual
expression of 105 genes and pCR. The expression of 14 genes was
significantly associated with pCR, including ERBB2, CCNE1,
genes involved in cell survival and migration (like FGFR4 and
GRB7), and genes related with DNA repair and replication
pathway (EXO1, ORC6L, and RRM2). On the contrary, the
expression of 21 genes was significantly associated with non-
pCR, including BCL2, ESR1, GATA3, KRT19, MYC, PGR,
PIK3CA, and SLC39A6 (Supplemental Data).
Residual Disease and Paired Samples
From Patients Not Achieving a pCR
Out of the 66 patients with residual disease at surgery, gene
expression was successfully performed in 28 surgical specimens
(42.4%). Residual subtype distribution was as follows: normal-
like (50.0%), luminal A (32.1%), HER2-enriched (14.3%), and
luminal B (3.5%). Of these 28 surgical specimens with residual
disease, 26 had pre- and post-treatment paired samples. As
expected, the baseline distribution of the intrinsic subtypes in
this cohort of patients that did not achieved a pCR, differed
from the overall cohort (Figure 5), with less proportion of HER2-
enriched subtype (42.3 vs. 64%) and nearly double the proportion
of luminal samples (42.3 vs. 19.1%). Regarding changes in
intrinsic subtypes in pre- and post-treatment paired samples
with residual disease, most of HER2-enriched tumors (81.8%)
converted to non-HER2-enriched, whereas 66.7% of luminal
A samples maintained the same subtype. Interestingly, in this
cohort of paired samples there were 7 conversions to HER2-
negative in residual disease (10 cases in the overall cohort).
Next, we analyzed changes in the expression of the 8
PAM50 signatures in those 52 pre- and post-treatment paired
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FIGURE 2 | Distribution of molecular subtypes at baseline. (A) In all patients (n = 89); (B) Patients with HR-negative disease (n = 40); (C) Patients with HR-positive
disease (n = 49).
samples. Most of them underwent significant changes: a decrease
in expression of HER2-enriched and luminal B signatures,
proliferation score, ROR-S, and ROR-P PAM50 signatures
were observed in most samples, as well as an important
increase in luminal A and normal-like signatures. On the
contrary, basal-like signatures showed no changes (Figure S3).
Regarding single genes, 90 changed significantly, with a false
discovery rate of <5%. Thirty-five genes, mostly related to
stroma (CAV1, VIM, MET, MMP) were overexpressed in post-
treatment samples compared to baseline, whereas 55 genes
decreased in expression (Supplemental Data). Most of the
downregulated genes in post-treatment samples are involved
in functions such as cell cycle and proliferation (EXO1,
CENPF, MKI67).
DISCUSSION
HER2-positive breast cancer is indeed a clinically and biologically
heterogeneous disease not fully recapitulated byHR status. In this
consecutive series of HER2-positive breast cancer patients treated
with trastuzumab-based primary chemotherapy, all the main
intrinsic molecular subtypes were identified by gene expression
analyses. Intrinsic subtype distribution differed significantly
between HR-negative and HR-positive tumors. Importantly,
HER2-enriched was the predominant subtype, not only in the
overall and HR-negative cohorts (64 and 75%, respectively) but
also in the HR-positive subgroup (55%). Tumor heterogeneity
within this series of HER2-positive breast cancer modulated
response to neoadjuvant treatment. The highest pCR rate was
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FIGURE 3 | Pathological complete response (pCR) in breast and axilla across the intrinsic subtypes of breast cancer in (A,B) the overall cohort; (C) Patients with
HR-positive disease (n = 49); (D) Patients with HR-negative disease (n = 40). HER2-E, HER2-enriched; non-HER2-E, non-HER2-enriched.
FIGURE 4 | Effect of PAM50 signatures (as continuous variables) on pathological complete response (pCR) in the univariate analysis (A) and after adjusting for
hormone receptor variables (B). Each signature has been standardized to have a mean of 0 and a standard deviation of 1. The size of the square is inversely
proportional to the standard error. Horizontal bars represent the 95% CIs of ORs. Statistically significant variables are shown in blue. Each gene signature has been
evaluated individually and ranked ordered based on the estimated OR. ROR-S, risk of recurrence score based on subtype; ROR-P risk of recurrence score based on
subtype and proliferation.
among patients with HER2-enriched tumors, which was more
than double the pCR rate of patients with non-HER2-enriched
tumors (65 vs. 31%), even in patients with HR-positive tumors
(48 vs. 23%).
HER2-enriched subtype has consistently been associated with
achieving the highest rate of pCR among HER2-positive tumors
(15, 17–21), even in the absence of chemotherapy, with just dual
HER2-blockade (21). In the clinical trials that have evaluated
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FIGURE 5 | Distribution of molecular subtypes in a cohort of patients with residual disease and paired baseline (A) and surgical specimens (B). HER2E,
HER2-enriched.
efficacy of HER2-targeted agents (e.g., trastuzumab, pertuzumab,
and lapatinib) in combination with neoadjuvant chemotherapy
or dual blockade alone, the pCR observed among the HER2-
enriched subtype varies between 41 and 70%, with the highest
rate being achieved with dual-HER2 blockade and chemotherapy.
In our study, the pCR rate of the HER2-enriched subgroup
was 65%, similar to that achieved in the CALGB study (70%),
one of the highest ever described in HER2-positive breast
cancer (15), regardless of treatment arm or HR status. It is
important to note that, in our study, treatment consisted of
single-trastuzumab given concomitantly with anthracycline-and-
taxanes-based neoadjuvant chemotherapy. The overall pCR rate
of 53% in our series is similar to that achieved in the ACOSOG
Z1041 trial (20), a trial designed to compare the pCR rate either
in a sequential or concurrent regimen of an anthracycline-and-
taxanes-based chemotherapy and trastuzumab (like the one used
in our study), which ultimately found no difference between both
arms. In this trial, cases classified as HER2-enriched subtype
by RNA-seq analysis were also more likely to achieve a pCR
compared to non-HER2-enriched tumors.
To our knowledge, our study is the first one to demonstrate
the association of five out of eight PAM50 signatures (HER2-
enriched, ROR-S, ROR-P, Basal-like, and Proliferation score)
with pCR, whereas luminal A signature was associated with
non-pCR. Moreover, HR-negative status and HER2-enriched
subtype (and signature) demonstrated the strongest association
in predicting pCR and luminal A signature with non-pCR.
Importantly, intrinsic subtype was an independent, additional
predictive factor of pCR to HR status.
Regarding baseline distribution of molecular subtypes, our
results are in accordance with previous reports such as the
PAMELA trial (21) and the APT trial (26, 27) where the largest
subset of baseline samples was classified as HER2-enriched (66.9
and 65%, respectively). In contrast, in the CALGB40601 (15)
study and the Cher-LOB trial (18), the proportion of HER2-
enriched subtype at baseline was similar to that of luminal
A and luminal B (31 and 27%, respectively) and luminal
subtypes predominated among HR-positive tumors. This fact
could explain why the overall pCR rate in the control arm in
the Cher-LOB trial (with the same treatment schema as in our
series) was surprisingly low (25%) (18). Another explanation is
that the PAMELA trial, the APT trial, and our study all used
the nCounter platform, whereas the CALGB40601 study used
RNAseq and Cher-LOB used microarrays.
Limited data exist regarding the distribution of molecular
subtypes in residual disease after neoadjuvant therapy and in
pre- and post-treatment paired samples. In the present study,
we examined changes in gene expression and molecular subtype
in paired samples of patients with residual disease. A lower
proportion of HER2-enriched subtypes and almost twice the
number of luminal tumors than in the overall cohort were
found at baseline. The most frequent subtype in not eradicated
post-treated tumors, excluding normal-like, was the luminal A
subtype, as occurred in the CALGB40601 study (15). In the paired
samples, most HER2-enriched tumors changed to non-HER2-
enriched, whereas most luminal A samples maintained the same
subtype. The observed changes in molecular subtype could be
attributed to reduced proliferation and/or changes in tumor and
stroma cellularity. Residual tumors also showed a substantial
modulation of genes, with downregulation of genes involved in
proliferation and cell cycle function and upregulation of those
related mostly to stroma. However, gene expression analyses
cannot distinguish between intra-tumor heterogeneity, stromal
alterations or a true treatment effect and may be a mixture of all
three. The down regulation of the HER2-enriched, luminal B and
proliferation PAM50 signatures (proliferation score, ROR-S, and
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ROR-P) and the overexpression of the luminal A and normal-like
signatures, seen in those paired samples from our study could be
explained by peritumoral stromal contamination. We note that
these analyses should be interpreted with caution, due to the
exploratory nature and small sample size of the study.
This study has several strengths and limitations. It was
done in a real-world setting, at a single institution, and it
has a long-term follow-up. Patients were homogeneously
treated with trastuzumab-based therapy and the study
also included evaluation of pre- and post-treatment paired
samples. Nevertheless, gene expression did not include immune
signatures, which other studies have found to be an independent
predictor of response to HER2 targeting beyond PAM50 intrinsic
subtypes (15, 18–20), and mutational status (such as PIK3CA)
was not analyzed either. Additionally, the current standard
neoadjuvant therapy for HER2-positive breast cancer include
dual-HER2-blockade with trastuzumab and pertuzumab.
Biologic heterogeneity within HER2-positive breast cancer
can determine response to treatment and prognosis as shown
in clinical trials, and in everyday clinical practice as shown in
our study. Yet, not all HER2-positive breast cancer patients
may need to be treated in the same manner. The combination
of HER2-targeted therapy alone (dual HER2 blockade with
or without endocrine therapy) has shown activity in a
substantial percentage of patients, eradicating HER2-positive
tumors without chemotherapy and with a favorable toxicity
profile (21, 28, 29). However, we need to be able to identify which
patients can benefit from this de-escalation strategy and if there
is a survival benefit in achieving a pCR with just dual blockade
and no chemotherapy. Interestingly, findings from additional
exploratory subgroup analyses in the NOAH study (30) showed
that the prognostic effect of pCR for event-free survival and
overall survival was statistically significant only in patients
treated with chemotherapy and trastuzumab and not in patients
treated with chemotherapy alone. What does seem clear is that
HER2 expression as a single biomarker of treatment response
is not enough to develop rational individualized therapeutic
regimens. There is an urgent need to find robust predictive
biomarkers of response or resistance to the anti-HER2 approach,
other than HER2-positivity, in order to individualize treatment
and identify different populations of patients who need more
treatment or others who may avoid unnecessary treatments and
their related toxicities. Serial changes in gene expression, tumor
cells or immune cells, as was done in the PAMELA trial (21, 31),
may identify early predictive markers of response or resistance
than just baseline or residual intrinsic subtypes alone.
CONCLUSION
Our data show that, outside of a clinical trial, PAM50 HER2-
enriched intrinsic subtype predicts pCR beyond HR status
following trastuzumab-based chemotherapy in HER2-positive
disease. The clinical value of intrinsic molecular subtype in
residual disease warrants further investigation.
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